



(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

COPY FROM PAPER

Substitute Info Form 1449A-RPTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/704469
		Filing Date	November 1, 2000
		First Named Inventor	Erik Karrer
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Attorney Docket Number	02-102020US		

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	AA	09/407,808		Maxygen, Inc.	09-28-1999
	AB	09/408,392		Maxygen, Inc.	09-28-1999
	AC	09/408,393		Maxygen, Inc.	09-28-1999
	AD	09/618,579		Maxygen, Inc.	07-16-2000
	AE	60/186,482		Maxygen, Inc.	06-02-2000
	AF	4,634,664		Engelman et al.	01-06-1987
	AG	4,634,666		Engelman et al.	01-06-1987
	AH	5,756,316		Schellenberger	05-26-1998
	AI	5,783,431		Peterson et al.	07-21-1998
	AJ	5,824,485		Thompson et al.	10-20-1998

FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	(if known)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AK	WO	00/00632	A1	Phylos, Inc
	AL	WO	00/09676	A1	Proteus
	AM	WO	00/42560	A2	Maxygen, Inc.
	AN	WO	00/42560	A3	Maxygen, Inc.
	AO	WO	00/42561	A2	Maxygen, Inc.
	AP	WO	00/42561	A3	Maxygen, Inc.
	AQ	WO	00/46344	A2	Diversa Corp.
	AR	WO	00/46344	A3	Diversa Corp.
	AS	WO	00/42559	A1	Maxygen, Inc.
	AT	WO	95/22625	A1	Stemmer
	AU	WO	96/33207	A1	Stemmer
	AV	WO	97/35957	A1	Stemmer
	AW	WO	98/42727	A1	SRI International

Examiner Signature	/Eric Dejong/	Date Considered	01/18/2007
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY FROM PARENT

Substitute for form 1449A-B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/704469
(use as many sheets as necessary)		Filing Date	November 1, 2000
		First Named Inventor	Erik Karrer
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
		Attorney Docket Number	02-102020US

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	AX	Balint and Lerrick (1993) "Antibody Engineering by Parsimonious Mutagenesis." <i>Gene</i> 137:109-118	
	AY	Chothia and Lesk (1987) "Canonical Structures for the Hypervariable Regions of Immunoglobulins." <i>J Mol Biol.</i> 196:901-917	
	AZ	Giver et al. (1998) "Combinatorial protein design by in vitro recombination." <i>Current Opinion in Chemical Biology</i> 2(3): 335-338.	
	BA	Gram et al. (1992) "In Vitro selection and affinity maturation of antibodies from a naïve combinatorial immunoglobulin library." <i>PNAS</i> 89:3576-3580	
	BB	Hawkins et al. (1992) "Selection of phage antibodies by binding affinity. Mimicking affinity maturation." <i>J. Mol Biol.</i> 226:889-896	
	BC	Hock (1997) "Antibodies for immuno-sensors: a review." <i>Analytica Chimica Acta</i> 347:177-186	
	BD	Huse et al. (1989) "Generation of a Large Combinational Library of the Immunoglobulin Repertoire in Phage Lambda." <i>Science</i> 246:1275-1281	
	BE	Jirholt et al. (1998) "Exploiting sequence space: shuffling in vivo formed complementarily determining regions into a master framework." <i>Gene</i> 215:471-476	
	BF	Litman et al. (1993) "Phylogenetic diversification on immunoglobulin genes and the antibody repertoire." <i>Mol Biol Evol</i> 10:60-72	
	BG	Low et al. (1996) "Mimicking somatic hypermutation: affinity maturation of antibodies displayed on bacteriophage using a bacterial mutator strain." <i>J. Mol Biol.</i> 260:359-368	
	BH	Marks et al. (1991) "By-passing immunization. Human antibodies from V-gene libraries displayed on phage." <i>J. Mol Biol.</i> 222:581-597	
	BI	Marks et al. (1992) "By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling." <i>Biotechniques</i> 10:779-782	
	BJ	Schier and Marks (1996) "Efficient in vitro affinity maturation of phage antibodies using BIACore guided selections." <i>Hum Antibodies Hybridomas</i> 7:95-105	
	BK	Stemmer et al. (1993) "Selection of an Active Single Chain Fv Antibody From a Protein Linker Library Prepared by Enzymatic Inverse PCR." <i>Biotechniques</i> 14(2):256-265	
	BL	Stemmer et al. (1995) "Single-step assembly of a gene and entire plasmid from large numbers of oligodeoxy-ribonucleotides." <i>Gene</i> 164:49-53	
	BM	Stemmer et al. (1997) "Molecular evolution of genes and pathways by DNA shuffling." <i>FASEB J.</i> 11:A1124	
	BN	Ward et al. (1989) "Binding activities of a repertoire of single immunoglobulin variable domains secreted from <i>Escherichia coli</i> ." <i>Nature</i> 341:544-546	

Examiner Signature	/Eric DeJong/	Date Considered	01/18/2007
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY FROM PARENT

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
Application Number	09/704469		
Filing Date	November 1, 2000		
First Named Inventor	Erik Karrer		
Group Art Unit	Unassigned		
Examiner Name	Unassigned		
Attorney Docket Number	02-102020US		
BO	Winter et al. (1994) "Making Antibodies by Phage Display Technology." <i>Annu Rev. Immunol.</i> 12:433-455		
BP	Wu et al. (1970) "An analysis of the sequences of the variable regions of bence jones proteins and myeloma light chains and their implications for anti-body complementarity." <i>J. Exo Med.</i> 132:211-250		

Examiner Signature	/Eric Dejong/	Date Considered	01/18/2007
-----------------------	---------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.